IP Library › Granted Patent US 11,136,565
Granted Patent B2
US 11,136,565 · App. 16/568,089 · Granted Oct 5, 2021

Modified archaeal family B polymerases

Inventors: Souad Naji (La Jolla, CA); Carl W. Fuller (New Jersey, NJ); Eli Glezer (Del Mar, CA); Andrew Spaventa (San Diego, CA)
Assignee: SINGULAR GENOMICS SYSTEMS, INC.
C12N9/1252C12P19/34C12Y207/07007
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,136,565
App. No.
16/568,089
Filed
Sep 11, 2019
Granted
Oct 5, 2021
Kind
B2
Art Unit
1656
USPC
435/69.1
Abstract

Provided herein are modified Archaeal family B polymerases derived from the Archaeal microorganism Pyrococcus abyssi that exhibit improved incorporation of nucleotide analogues utilized in DNA sequencing.

Claims (75)

1. A polymerase comprising an amino acid sequence that is at least 85% identical to a continuous 500 amino acid sequence within SEQ ID NO: 1; comprising the following amino acids:

an alanine at amino acid position 409 or at a position corresponding to amino acid position 409;

a glycine at amino acid position 410 or at a position corresponding to amino acid position 410; and

a proline at amino acid position 411 or at a position corresponding to amino acid position 411.

2. The polymerase of claim 1 , wherein the polymerase comprises an amino acid sequence that is at least 95% identical to a continuous 500 amino acid sequence within SEQ ID NO: 1.

3. The polymerase of claim 1 , wherein the polymerase further comprises an amino acid substitution mutation between position 129 and 316 of SEQ ID NO: 1, inclusive of positions 129 and 316.

4. The polymerase of claim 1 , wherein the polymerase further comprises an amino acid substitution mutation at positions 129, 141, and 143.

5. The polymerase of claim 1 , wherein the polymerase further comprises an alanine substitution, a glycine substitution, a valine substitution, a leucine substitution, or an isoleucine substitution mutation at position 129.

6. The polymerase of claim 1 , wherein the polymerase further comprises an alanine substitution mutation at position 143.

7. The polymerase of claim 1 , wherein the polymerase further comprises an alanine substitution mutation at position 144.

8. The polymerase of claim 1 , wherein the polymerase further comprises a leucine or valine substitution mutation at position 486.

9. The polymerase of claim 1 , wherein the polymerase further comprises serine at position 515.

10. The polymerase of claim 1 , wherein the polymerase further comprises isoleucine at position 590.

11. The polymerase of claim 1 , comprising the following mutations:

M129A, D141A, T144A, E143A, L409A, Y410G, A486V, T515S, and T590I;

M129A, D141A, E143A, L409A, Y410G, and A486V;

M129A; D141A; T144A; E143A; L409A; Y410G; A486V; T515S; T590I; and G153E;

M129A; D141A; T144A; E143A; L409A; Y410G; A486V; T515S; T590I; G153E; and K712E;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; and I522L;

M129A; D141A; E143A; T144A; L409A; Y410G; A486L; T515S; T590I; and G153E;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; K602A;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; and N735A;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; and K477A;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; and K478A;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; and L479S;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; K477A; K478A; and L479S;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; and A639L;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; and R705A;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; and E718A;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; and R713A;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; and D215A;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; and D315A;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; D215A; and D315A;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; K712E; and I522L;

M129A; D141A; E143A; T144A; L409A; Y410G; A486L; T515S; T590I; G153E; and K712E;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; K712E; and K602A;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; K712E; and N735A;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; K712E; and K477A;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; K712E; and K478A;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; K712E; and L479S;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; K712E; K477A; K478A; and L479S;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; K712E; and A639L;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; K712E; and R705A;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; K712E; and E718A;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; K712E; and R713A;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; K712E; and D215A;

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; K712E; and D315A; or

M129A; D141A; E143A; T144A; L409A; Y410G; A486V; T515S; T590I; G153E; K712E; D215A; and D315A.

12. A polymerase comprising an amino acid sequence comprising SEQ ID NO: 1; further comprising the following mutations:

M129A, D141A, E143A, L409A, Y410G, P411L, and A486V;

M129A, D141A, E143A, L409A, Y410G, P411G, and A486V;

M129A, D141A, E143A, L409A, Y410G, P411S, and A486V;

M129A, D141A, E143A, L409A, Y410G, P411T, and A486V;

M129A, D141A, E143A, L409A, Y410G, P411A, and A486V;

M129A, D141A, E143A, L409Q, Y410A, P411I, and A486V; or

M129A, D141A, E143A, L409G, Y410G, P411I, and A486V.

13. The polymerase of claim 1 , which exhibits an increased rate of incorporation of modified nucleotides, relative to a wild-type P. abyssi DNA polymerase.

14. The polymerase of claim 1 , wherein the amino acid sequence is at least 99% identical to SEQ ID NO: 1.

15. The polymerase of claim 11 , wherein the amino acid sequence is at least 99% identical to SEQ ID NO: 1.

16. The polymerase of claim 12 , wherein the amino acid sequence is at least 99% identical to SEQ ID NO: 1.

17. The polymerase of claim 1 , wherein the polymerase is truncated at the C-terminus.

18. A polymerase comprising an amino acid sequence that is at least 85% identical to a continuous 500 amino acid sequence within SEQ ID NO: 1, comprising an alanine at amino acid position 409 or at a position corresponding to amino acid position 409; and a glycine at amino acid position 410 or at a position corresponding to amino acid position 410.

19. The polymerase of claim 1 , wherein the polymerase is capable of incorporating a reversible terminator moiety.

20. The polymerase of claim 18 , wherein the polymerase is capable of incorporating a reversible terminator moiety.

21. The polymerase of claim 19 , wherein the reversible terminator moiety has the formula:

wherein R″ is unsubstituted C 1 -C 4 alkyl; or

wherein R A and R B are hydrogen or alkyl, wherein at least one of R A or R B are hydrogen to yield a steroisomeric probe, and R C is the remainder of the reversible terminator moiety.

22. The polymerase of claim 19 , wherein the reversible terminator moiety has the formula

wherein R A and R B are hydrogen or alkyl, wherein at least one of R A or R B are hydrogen to yield a steroisomeric probe, and R C is the remainder of the reversible terminator moiety.

23. The polymerase of claim 1 , wherein the polymerase further comprises one or more amino acid substitution mutations at position 129, 141, 142, 143, 144, 209, 210, 213, 214, 215, 274, 275, 311, or 315.

24. The polymerase of claim 1 , wherein the amino acid sequence is at least 90% identical to SEQ ID NO: 1.

25. The polymerase of claim 1 , wherein the polymerase further comprises an amino acid substitution mutation at position 515.

26. The polymerase of claim 1 , wherein the polymerase further comprises a valine substitution mutation at position 486.

27. The polymerase of claim 17 , wherein the polymerase is truncated to remove at least 20 amino acids from the C-terminus.

28. The polymerase of claim 17 , wherein the polymerase is truncated to remove 5 to 16 amino acids from the C-terminus.

Assignments (2)
SECURITY INTEREST Recorded Mar 7, 2025
From: SINGULAR GENOMICS SYSTEMS, INC.
To: FIRST-CITIZENS BANK & TRUST COMPANY
Reel/Frame 070440/0465 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2019
From: FULLER, CARL W.; GLEZER, ELI; SPAVENTA, ANDREW; NAJI, SOUAD
To: SINGULAR GENOMICS SYSTEMS, INC.
Reel/Frame 050347/0610 →
Continuity (2)
Provisional Application 62729875 · Sep 11, 2018
Related Publication 20200080065A1 · Mar 12, 2020
Cited By (4)
US 12,344,867 US 12,454,683 US 12,630,808 US 12,668,834